Business Context and Reporting Period
Company: NanoViricides, Inc. (NNVC)
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2013
Business Overview: NanoViricides is a development-stage biopharmaceutical company focused on creating nanomedicine therapeutics ("nanoviricides") to treat viral diseases. The company utilizes a proprietary platform to design drugs that mimic host cell surfaces to neutralize viruses. As of the reporting date, the company had no commercialized products and generated no revenue.
Key Financial Metrics
| Metric | Year Ended June 30, 2013 | Year Ended June 30, 2012 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(8,875,667) | $(6,207,207) |
| Net Loss Per Share | $(0.19) | $(0.15) |
| Research & Development Expenses | $4,292,909 | $4,265,933 |
| General & Administrative Expenses | $3,207,859 | $1,815,816 |
| Cash and Cash Equivalents (End of Period) | $13,923,245 | $14,274,985 |
| Accumulated Deficit | $(38,299,783) | $(29,424,116) |
| Stockholders' Equity | $8,009,654 | $13,850,191 |
Debt and Liquidity: The company reported no long-term debt as of June 30, 2013, excluding $6 million in Series B Convertible Debentures issued in February 2013. Working capital was approximately $598,000. Management estimated cash reserves were sufficient to fund operations for approximately two years following the reporting period.
Material Changes and Operational Highlights
- Increased Operating Expenses: General and administrative expenses increased by approximately $1.39 million year-over-year, driven by non-R&D expenditures associated with drug development and corporate governance improvements. R&D expenses remained relatively flat, increasing by only $27,000.
- Financing Activities: During the fiscal year, the company raised $6 million via Series B Convertible Debentures and redeemed remaining Series C Preferred Stock. Subsequent to the reporting period (September 2013), the company completed a registered direct offering raising approximately $10.3 million (net proceeds ~$9.6 million).
- Corporate Governance and Listing: The company improved its board composition by adding independent directors. Following a 3.5-for-1 reverse stock split in September 2013, the company's common stock was uplisted to the NYSE MKT (New York Stock Exchange MKT) under the symbol "NNVC."
- Manufacturing: The company is constructing a cGMP (current Good Manufacturing Practices) facility in Shelton, CT, via a related party (Inno-Haven, LLC), to enable clinical batch production.
Guidance, Outlook, and Risks
Outlook and Pipeline: The company is advancing six primary drug candidates, all currently in pre-clinical stages:
- FluCide: Injectable (for hospitalized patients) and Oral (for outpatients) formulations for broad-spectrum influenza. The injectable version is the lead candidate for an Investigational New Drug (IND) application.
- HIVCide: Anti-HIV candidate showing efficacy comparable to HAART cocktails in animal models with potential for long-acting effects.
- DengueCide: Received "Orphan Drug Designation" from the FDA in 2013, offering potential tax credits and priority review vouchers.
- Other Programs: Eye drops for viral infections, HerpeCide (herpes), and candidates for Rabies and Ebola/Marburg.
Capital Requirements: Management estimates an additional $10 million to $15 million will be required over the next 36-48 months to advance the Oral FluCide and DengueCide candidates to IND filing and to fund initial human clinical trials for the Injectable FluCide. The company anticipates needing further financing beyond June 2015.
Risks and Contingencies:
- Development Risk: All products are pre-clinical; there is no assurance that candidates will prove safe or effective in human trials or receive regulatory approval.
- Liquidity Risk: The company has a history of losses and relies on continued equity or debt financing to sustain operations.
- Related Party Transactions: The company relies on TheraCour Pharma, Inc. (controlled by the CEO) for core technology licensing and manufacturing, and Inno-Haven, LLC (controlled by the CEO) for facility construction.
- Legal Proceedings: The company is defending against shareholder derivative lawsuits in Nevada and Colorado regarding inspection of books and records and alleged fiduciary breaches.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $13.9 million cash balance (as of June 30, 2013) plus the subsequent $9.6 million net proceeds to cover the estimated $10-15 million additional funding requirement for IND filings and clinical trials.
- Related Party Agreements: Review the terms of the lease agreement with Inno-Haven, LLC for the cGMP facility and the licensing agreement with TheraCour Pharma, Inc., specifically regarding termination rights and cost structures.
- Regulatory Milestones: Monitor the timeline for the filing of the IND application for the Injectable FluCide (NV-INF-1) and the status of the cGMP facility construction and validation.
- Legal Status: Track the resolution of the pending shareholder derivative lawsuits (Yidam, Ltd. v. NanoViricides, Inc.) in Nevada and Colorado.
- Dilution: Assess the impact of the recent reverse stock split and the registered direct offering on existing shareholder equity and the potential for future dilution given the company's capital needs.